BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial : The need for a new pre-clinical treatment rationale - Bracht, Jillian (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Karachaliou, Niki (Hospital Universitari Sagrat Cor. Institut Oncològic Rosell) ; Bivona, Trever (University of California. Department of Medicine) ; Lanman, Richard B. (Guardant Health) ; Faull, Iris (Guardant Health) ; Nagy, Rebecca J. (Guardant Health) ; Drozdowskyj, Ana (PIVOTAL SL) ; Berenguer, Jordi (Institut Universitari Quirón-Dexeus. Laboratori de Biologia Molecular) ; Fernandez-Bruno, Manuel (Hospital Universitario Sagrat Cor. Institut Oncològic Rosell) ; Molina-Vila, Miguel Ángel (Institut Universitari Quirón-Dexeus. Laboratori de Biologia Molecular) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
 
Comments (0) | Reviews (0)
Be the first to review this document.

Add review

Rate this article:
Give a title to your review:
Write your review:
Note: you have not defined your nickname.
N/D will be displayed as the author of this comment.